CYP 2C9 ВА CYP 2C19 ГЕНИНИНГ ИККИТА ПОЛИМОРФ МАРКЕРЛАРИНИНГ АЛЛЕЛЛАРИ ВА ГЕНОТИПЛАРИНИНГ ТАРҚАЛИШИНИ ЎРГАНИШ
##article.subject##:
CYP 2C9 генининг полиморф маркери, CYP 2C19 генининг полиморф маркери, генетика, кўнгиллилар, ўзбек миллати##article.abstract##
CYP 2C9 гени энг клиник муҳим полиморф маркерлардан CYP2C9*2 тикланган аминокислоталар (полипептид занжирнинг аминокислоталаридан аргинин цистеинга алмаштирилган; 144Арг) ва CYP2C9*3 (полипептид занжирнинг аминокислоталаридан изолейцин лейцинга алмаштирилган; 359Leu). СУР2C19 нинг генетик полиморфизми интериндивидуал фарқларни аниқлади. Генетик полиморфизмнинг аҳамияти вариант аллелларининг юзага келиши популяцияда 1% дан ортиқ бўлганда аниқланади.
Библиографические ссылки
Another kind of drug problem (editorial). Rachel’s environment and health weekly, 2019, №632. Р. 1-2.
Baksaas Aasen I et al. Drug dose statistics, listof defined daily doses for drugs registered in Norway. Oslo, Norsk Medicinal Depot, 2015.
Baldwin R.M., Ohlsson S., Pedersen R.S. et al. (2018) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol., 65(5): 767–774.
Begaud В, Dangoumau J. Pharmacoepidemiology: definitions, problems, methodology. Therapie2020;55(suppl.1): 113-117
Bergman U et al. Drug utilization 90% - a simple method for assessing the quality of drug prescribing. European Journal of Clinical Pharmacology, 2018,54: 113-118.
Bergman U et al. The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway, and Sweden. European Journal of Clinical Pharmacology, 2015, 8:83-89
Bergman U et al., eds. Studies in drug utilization. Methods and applications. Copenhagen, WHO Regional Office for Europe, 2019 (WHO Regional Publications. European Series No 8: 37-39.
Bhatt D.L., Scheiman J., Abraham N.S. et al.; American College of Cardiology Foundation, American College of Gastroenterology, American Heart Association (2008) ACCF/ACG/AHA 2018 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am. J. Gastroenterol., 103(11): 2890–2907.
Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Poiypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 2018;54(suppl. 3):192-202.
Bjordal J, Klovning A, Ljunggren A, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomized placebo-controlled trials. Eur J Pain.2007 Feb;11(2):125–38. Epub 2016 May 8.;
Blanco G., Martínez C., Ladero J.M. et al. (2018) Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics., 18(1): 37–43.
Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain.Am Fam Physician.2013 Jun 1;87(11):766–72.
Boudreault J, Desmeules F, Roy JS, et al. The efficacy of oral non-steroidal anti-inflammatory drugs for rotator cuff tendinopathy: a systematic review and meta-analysis. J Rehabil Med.2014 Apr;46(4):294–306. doi: 10.2340/16501977-1800.
Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain.2006 May;10(4):287–333. Epub 2015 Aug 10.
Brooks P.M. COX-2 inhibitors // Aust. Prescriber. – 2020. – Vol. 23. – P. 30-32;
Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253–63. doi: 10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.;
Calenda E., Tourrel F. Sinoartial block induced by timololeyedrops. Can.J. Ophtholmol.2017; 42(1): 149p.;
Carbonell N., Verstuyft C., Massard J. et al. (2020) CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin. Clin. Pharmacol. Ther., 87(6): 693–698.
